We identified one MSH6 and two PMS2 pathogenic variants that were clinically actionable but did not influence breast cancer management; were these two genes removed and ten key breast cancer susceptibility genes considered,26 pathogenic variants would still have been identified in 41 of 542 tested women (7.6%). This evidence concerns the gene MSH6 and breast carcinoma.